The antiviral treatment of chronic hepatitis B is a systematic project that must be carried out under the guidance of a hepatologist, including the selection of drugs, monitoring during treatment, drug replacement and adjustment, and discontinuation or termination of treatment. The existing antiviral therapy is divided into two categories of drugs, one is the injectable interferon class and the other is the oral definitive nucleoside class. The interferon class is subdivided into two types: 1) domestic short-acting interferon, which needs to be injected every other day, and 2) imported long-acting interferon, which needs to be injected once a week; regarding oral nucleoside antiviral drugs, there are currently four types available for purchase: lamivudine, adefovir, entecavir, and telbivudine. Each of these two types of treatment has advantages and disadvantages. Interferon is a shorter course of treatment, generally 1 year, a few need to extend to 1.5 or 2 years, the treatment effect varies from 30% to 50%, the main effect is reflected in the transformation of major triplets into minor triplets, hepatitis B virus control below the detection line, liver function is stable and normal for a long time, liver disease is stable and does not progress, less patients can achieve surface antigen negative. The disadvantage of interferon is that the side effects are large, but most patients can tolerate it, and the side effects can disappear after stopping the drug; another part of patients are contraindications to interferon treatment and are not suitable for treatment with interferon. The advantages of oral nucleoside analogs are that they have few side effects, are taken orally once a day, are convenient, have basically no contraindications, can be suitable for all patients except those allergic to the drug, have a high response rate during treatment, can quickly control viral replication and stop disease progression. The disadvantage of oral nucleoside analogs is that the treatment time is long, usually at least 3-5 years, and should not be discontinued at will, and easy to rebound after discontinuation; in addition, with the prolongation of the medication time, drug resistance is likely to occur, of course, the chance of drug resistance for each drug is unequal, there are high and low. It should be said that both types of treatment can be suitable for you, mainly according to your marriage and childbirth history, the nature of work, economic status, other physical conditions to choose. The drug selection process requires full communication and discussion with the patient himself, combined with the patient’s own individual characteristics to choose. The treatment process is also relatively long, ranging from 1 year (e.g., injectable interferon) to more than 3-5 years (note that there is no upper limit for the word “more than”, e.g., oral nucleoside analogs). Therefore, in the course of longer-term treatment, a variety of complications may arise and need to be closely monitored under the guidance of a specialist, such as initial assessment of efficacy, monitoring of side effects and drug resistance. In case of poor efficacy, side effects or drug resistance, the doctor will then communicate with the patient and discuss the next step of treatment, whether to change, add, suspend, or terminate the treatment. Some patients adjust their treatment plan because of the need for fertility; others need to discontinue their treatment for observation because the treatment is working well, etc. All of the above clinical problems require communication, communication and discussion with the specialist. Therefore, we would like to remind our patients that they should not use their own medication, or change or stop their medication without the guidance of a specialist. Frequent irregular and unsystematic antiviral treatment is wasteful, may aggravate the disease, and may increase the drug resistance of the virus, making the future treatment difficult.